Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125612821 | 12561282 | 1 | I | 20160513 | 20160705 | 20160715 | 20160715 | EXP | GB-MHRA-MIDB-5B49B96D-5342-4953-BAA2-958D70213175 | GB-TEVA-674537ACC | TEVA | 71.00 | YR | M | Y | 0.00000 | 20160715 | PH | GB | GB |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125612821 | 12561282 | 1 | PS | CITALOPRAM | CITALOPRAM HYDROBROMIDE | 1 | Oral | 40 MILLIGRAM DAILY; | U | U | 77232 | 40 | MG | TABLET | QD | ||||
| 125612821 | 12561282 | 2 | I | NAPROXEN. | NAPROXEN | 1 | Oral | 1000 MILLIGRAM DAILY; | U | U | 74129 | 500 | MG | TABLET | BID | ||||
| 125612821 | 12561282 | 3 | I | CIPROFLOXACIN. | CIPROFLOXACIN | 1 | Oral | 1000 MILLIGRAM DAILY; | 7000 | MG | Y | U | 74124 | 500 | MG | BID | |||
| 125612821 | 12561282 | 4 | C | AVAMYS | FLUTICASONE FUROATE | 1 | Nasal | 55 MICROGRAM DAILY; 27.5 MICROGRAMS | 0 | 55 | UG | NASAL SPRAY | QD | ||||||
| 125612821 | 12561282 | 5 | C | CETIRIZINE | CETIRIZINE HYDROCHLORIDE | 1 | Oral | 10 MILLIGRAM DAILY; | 0 | 10 | MG | TABLET | QD | ||||||
| 125612821 | 12561282 | 6 | C | FERROUS SULFATE. | FERROUS SULFATE | 1 | Oral | 600 MILLIGRAM DAILY; | 0 | 200 | MG | TABLET | TID | ||||||
| 125612821 | 12561282 | 7 | C | LAXIDO | POLYETHYLENE GLYCOL 3350POTASSIUM CHLORIDESODIUM BICARBONATESODIUM CHLORIDE | 1 | Oral | 0 | 13.7 | G | POWDER FOR ORAL SOLUTION | ||||||||
| 125612821 | 12561282 | 8 | C | LOSARTAN. | LOSARTAN | 1 | 50 MILLIGRAM DAILY; | 0 | 50 | MG | TABLET | QD | |||||||
| 125612821 | 12561282 | 9 | C | NASEPTIN | CHLORHEXIDINE HYDROCHLORIDENEOMYCIN SULFATE | 1 | Topical | 0 | CREAM | ||||||||||
| 125612821 | 12561282 | 10 | C | NEFOPAM | NEFOPAM | 1 | Oral | 90 MILLIGRAM DAILY; | 0 | 30 | MG | TABLET | TID | ||||||
| 125612821 | 12561282 | 11 | C | PREDNISOLONE. | PREDNISOLONE | 1 | Oral | 20 MILLIGRAM DAILY; | 140 | MG | 0 | 20 | MG | TABLET | QD | ||||
| 125612821 | 12561282 | 12 | C | HYDROCORTISONE. | HYDROCORTISONE | 1 | Topical | 0 | |||||||||||
| 125612821 | 12561282 | 13 | C | MICONAZOLE. | MICONAZOLE | 1 | Topical | 0 | |||||||||||
| 125612821 | 12561282 | 14 | C | OMEPRAZOLE. | OMEPRAZOLE | 1 | Oral | 20 MILLIGRAM DAILY; | 0 | 20 | MG | QD | |||||||
| 125612821 | 12561282 | 15 | C | PARACETAMOL | ACETAMINOPHEN | 1 | Oral | 500MG-1G | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 125612821 | 12561282 | 3 | Upper respiratory tract infection |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 125612821 | 12561282 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 125612821 | 12561282 | Drug interaction | |
| 125612821 | 12561282 | Seizure |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 125612821 | 12561282 | 3 | 20160506 | 20160513 | 0 | |
| 125612821 | 12561282 | 11 | 20160506 | 20160511 | 0 |